China Scar Treatment Market To Surpass US$ 5,317.7 Million By 2027

SEATTLE - June 15, 2021 - PRLog -- Burn injury or other trauma condition, including surgery can lead to a scar. Several factors impact the appearance and treatment of scar after an injury.

China Scar Treatment Market is estimated to account for US$ 2,422.5 Mn in terms of value by the end of 2019.

China Scar Treatment Market: Opportunities

Increasing R&D in skin defect reconstruction is expected to offer lucrative growth opportunities for market players over the forecast period.

Key Takeaways:

The Aesthetic Lasers segment in the China scar treatment market was valued at US$ 1,119.8 Mn in 2018 and is expected to reach US$ 2,717.3 Mn by 2027 at a CAGR of 10.4% during the forecast period. The growth of the segment is attributed to increasing number of aesthetic surgical procedures in the country

The laser treatment segment held dominant position in China scar treatment market in 2018, accounting for 45% share in terms of volume, followed by topical treatment and invasive surgical treatment, respectively.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3154

Regulations

The market is regulated by China's Good Manufacturing Practices and FDA.

Manufacturer needs to establish a quality management system as China's FDA guidelines to maintain product consistency and quality throughout

Manufacturer are required to strictly implement GMP with integrity without any falsification

Measurability of quality, consistency and efficacy needs to be well documented to ensure pharmacovigilance

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/china-scar-treatment-market-3154

China Scar Treatment Market: Competitive Landscape

Major players operating in China scar treatment market include, Cynosure, Inc., Syneron Medical Ltd., Mölnlycke Health Care, Ostar Beauty Sci-Tech Co., Ltd., Shanghai Fosun Pharmaceutical Co. Ltd., Beijing Toplaser Technology Co., Ltd., Merz Pharma, and Luca Pharmaceuticals.

Key Developments

For instance, in November 2019, AVITA Medical collaborated with the Gates Center for Regenerative Medicine at the University Of Colorado School Of Medicine to establish proof-of-concept and explore further development of a spray-on treatment of genetically modified cells for patients with epidermolysis bullosa (EB) and other genetic skin disorders.

In December 2019, Janssen Biotech, Inc. entered a definitive agreement to acquire all rights to the investigational compound bermekimab – an anti-IL-1alpha monoclonal antibody for the treatment of atopic dermatitis and hidradenitis suppurativa— from XBiotech Inc.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3154